Related Experiment Video
Updated: Jul 23, 2025
09:19
In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time
Published on: May 24, 2020
9.1K
Immunothrombosis and its underlying biological mechanisms
Arthur Cunha De Nardi1, Andréa Coy-Canguçu1, Atena Saito1
1Pontifícia Universidade Católica de Campinas (PUCC), Faculdade de Medicina, Campinas, Brazil.
Hematology, Transfusion and Cell Therapy
|July 14, 2023
Summary
The link between blood clotting (coagulation) and immunity can cause harmful thrombosis when deregulated, a process called immunothrombosis. Understanding immunothrombosis is key to developing new therapies for conditions like COVID-19.
Area of Science:
- * Immunothrombosis research bridges hematology, immunology, and infectious disease.
- * Focuses on the evolutionary link between coagulation and innate immunity.
Background:
- * Physiological interplay between immunity and coagulation aids pathogen defense.
- * Deregulated hemostasis and immunity lead to pathological immunothrombosis.
- * Immunothrombosis underlies thrombotic disorders, including COVID-19.
Purpose of the Study:
- * To review molecular and cellular mechanisms of immunothrombosis.
- * To highlight the role of neutrophil extracellular traps (NETs), platelets, and coagulation.
- * To examine how hemostasis deregulation worsens conditions like COVID-19.
Main Methods:
- * Comprehensive literature review of immunothrombosis.
- * Analysis of molecular pathways involving NETs, platelets, and coagulation.
- * Case study approach using COVID-19 as a clinical model.
Main Results:
- * Extreme inflammation alters coagulation and immune cell function, increasing coagulability.
- * Immunothrombosis involves key players like NETs, platelets, and the coagulation cascade.
- * Deregulated hemostasis significantly exacerbates patient conditions in thrombotic disorders.
Conclusions:
- * Understanding immunothrombosis is crucial for developing effective therapies.
- * Targeting mechanisms of immunothrombosis can prevent and treat thrombosis in COVID-19 and other diseases.
- * Further research into hemostasis and immunity interplay is needed for improved patient outcomes.
Related Concept Videos
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
763
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
763
01:24Disorders of Hemostasis
999
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
999
01:30Venous Thrombosis I: Introduction
13
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
13
01:20Extrinsic and Intrinsic Pathways of Hemostasis
8.4K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
8.4K
01:29Venous Thrombosis III: Interprofessional Care
10
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
10
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K